NSE - Delayed Quote INR

Aarti Drugs Limited (AARTIDRUGS.NS)

Compare
488.60 -6.40 (-1.29%)
At close: 3:30 PM GMT+5:30
Currency in INR All numbers in thousands
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
24,228,100.00
25,285,800.00
27,160,500.00
24,886,458.00
21,547,798.00
--
Cost of Revenue
15,911,900.00
16,777,200.00
18,885,100.00
19,849,832.00
15,544,706.00
--
Gross Profit
8,316,200.00
8,508,600.00
8,275,400.00
5,036,626.00
6,003,092.00
--
Operating Expense
5,865,100.00
5,858,500.00
5,722,600.00
2,058,657.00
2,044,180.00
--
Operating Income
2,451,100.00
2,650,100.00
2,552,800.00
2,977,969.00
3,958,912.00
--
Net Non Operating Interest Income Expense
-336,900.00
-335,200.00
-332,900.00
-231,909.00
-236,349.00
--
Pretax Income
2,159,800.00
2,355,300.00
2,241,800.00
2,699,551.00
3,690,139.00
--
Tax Provision
590,800.00
639,400.00
578,200.00
649,593.00
886,156.00
--
Net Income Common Stockholders
1,568,100.00
1,714,200.00
1,663,100.00
2,050,386.00
2,804,130.00
--
Diluted NI Available to Com Stockholders
1,568,100.00
1,714,200.00
1,663,100.00
2,050,386.00
2,804,130.00
--
Basic EPS
18.40
18.56
17.97
22.14
30.09
--
Diluted EPS
18.40
18.56
17.97
22.14
30.09
--
Basic Average Shares
90,290.00
91,940.00
92,600.00
92,600.00
93,200.00
--
Diluted Average Shares
91,935.00
91,940.00
92,600.00
92,600.00
93,200.00
--
Rent Expense Supplemental
--
--
600.00
600.00
600.00
600.00
Total Expenses
21,777,000.00
22,635,700.00
24,607,700.00
21,908,489.00
17,588,886.00
--
Net Income from Continuing & Discontinued Operation
1,568,100.00
1,714,200.00
1,663,100.00
2,050,386.00
2,804,130.00
--
Normalized Income
1,568,100.00
1,714,200.00
1,663,100.00
2,063,193.28
2,808,855.82
--
Interest Income
--
--
6,992.00
7,169.00
25,958.00
11,257.00
Interest Expense
336,900.00
335,200.00
332,900.00
207,480.00
229,574.00
--
Net Interest Income
-336,900.00
-335,200.00
-332,900.00
-231,909.00
-236,349.00
--
EBIT
2,496,700.00
2,690,500.00
2,574,700.00
2,907,031.00
3,919,713.00
--
EBITDA
3,019,000.00
3,205,000.00
3,077,900.00
3,407,520.00
4,418,548.00
--
Reconciled Cost of Revenue
15,911,900.00
16,777,200.00
18,885,100.00
19,849,832.00
15,544,706.00
--
Reconciled Depreciation
522,300.00
514,500.00
503,200.00
500,489.00
498,835.00
--
Net Income from Continuing Operation Net Minority Interest
1,568,100.00
1,714,200.00
1,663,100.00
2,050,386.00
2,804,130.00
--
Total Unusual Items Excluding Goodwill
--
--
--
-16,865.00
-6,219.00
--
Total Unusual Items
--
--
--
-16,865.00
-6,219.00
--
Normalized EBITDA
3,019,000.00
3,205,000.00
3,077,900.00
3,424,385.00
4,424,767.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
--
--
--
-4,057.72
-1,493.18
--
3/31/2020 - 9/19/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers